Teva’s Benign Opioid Settlement Isn’t in the Bag Yet

Investors shouldn’t be surprised if a familiar risk to Teva Pharmaceutical Industries soon resurfaces. Last October, Teva agreed to a global settlement framework with several state attorneys general to discharge thousands of lawsuits against the company related to the opioid crisis. According to last year’s agreement, under which the company wouldn’t admit liability, Teva would donate buprenorphine naloxone tablets worth approximately $23 billion at the drug’s list price. Buprenorphine naloxone, also sold under the brand name…


Source link

error: Content is protected !!